Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Acquisition Should Increase Routine Flow Cytometry Diagnostic Use in Research and Clinical Practice

By BiotechDaily International staff writers
Posted on 13 Aug 2013
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
A major American producer of instruments for biomedical testing has acquired access to flow cytometry reagents that were among the first of this genre to be both dry and temperature-stable with CE marking for routine in vitro diagnostic use in Europe.

Beckman Coulter Life Sciences (Indianapolis, IN, USA), which develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing has acquired the flow cytometry business assets of the life science technology company ReaMetrix India Pvt. Ltd. (Bangalore, India).

Beckman Coulter Life Sciences' diagnostic systems are found in hospitals and other critical care settings around the world and generate data used by physicians to diagnose disease, make treatment decisions, and monitor patients. In the research sector, their instruments have been applied to complex biological problems including causes of disease and potential new therapies or drugs. Acquisition of ReaMetrix is expected to help Beckman Coulter to widen its tool and technology offerings that would simplify the sample preparation process and provide highly standardized reagent combinations to cytometry laboratories around the globe. The deal provides it with temperature-stable, single-dose, multi-color antibody cocktails targeting two key segments for flow cytometry - HIV monitoring and clinical research.

“This acquisition provides both immediate opportunity and long-term value,” said Mario Koksch, vice president and general manager of the cytometry business unit at Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We will be able to offer customers an extended line of market leading technology while expanding our reach within two key segments for flow cytometry—HIV monitoring and clinical research.”

“Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation,” said Bala S. Manian, CEO of ReaMetrix India Pvt. Ltd. “The development of room temperature stable unitized flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world. ”

Related Links:
Beckman Coulter Life Sciences
ReaMetrix India Pvt. Ltd.


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.